Incretins are a group of metabolic hormones that stimulate on the decrease in blood glucose levels. Incretin-based drugs include dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like peptide-1 receptor agonists, which are a relatively new group of drugs used in the treatment of type 2 diabetes. These drugs are associated with a low risk of hypoglycemia and have the favorable effect on body weight. Oral anti-diabetic drugs fail to maintain the desired normal levels of glucose, particularly during postprandial conditions, this has resulted in a strong need for better therapeutics like incretin-based drugs. Incretin-based drugs increase the secretion of insulin by acting on pancreatic beta cells and also inhibits the release of glucagon by acting on the pancreatic alpha cells. Incretin-based drugs namely Incretin mimetics (GLP-1 agonist) and DPP-4 inhibitors work on the antidiabetic principle of incretin hormone.
The major drivers of global incretin-based drugs market are the sedentary lifestyle, rising old age population, increasing rate of cardiovascular diseases, obesity, increasing incidence of diabetes, and raising awareness of diabetes. Also, a large number of pre-diagnosed and undiagnosed patients across the globe are further fuel the market growth for incretin-based drugs. But the lack of reimbursement, poor accessibility to drugs especially in developing countries, high safety concerns and high treatment cost associated with incretin-based drugs are likely some of the restraints of incretin-based drugs market.
Several large cohorts of patients with diabetes, the use of incretin-based drugs as compared with combinations of oral antidiabetic drugs were not associated with an increased risk of hospitalization for heart failure.
Approximately 26 million diabetic patients in the United States and 35 million in the European Union alone is growing prevalence of diabetes worldwide posing a major public health challenge. Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are committed to ensuring the safety of drug products marketed for the treatment of diabetes and post marketing reports of pancreatitis and pancreatic cancer in patients taking certain antidiabetic medications like incretin-based drugs. Working in parallel, these agencies have reviewed epidemiologic data, clinical trial data and nonclinical toxicology studies related to blood glucose lowering drug products like exenatide and sitagliptin which are incretin-based drugs that stimulate postprandial insulin release by potentiating the incretin hormone pathways. The results highlighted that these incretin-based drugs reduce body weight and have better cardiovascular outcomes.
Regionally, the market can be segmented into North America, Eastern Europe, Western Europe, Asia-Pacific excluding Japan, Japan, Latin America and the Middle East and Africa. Global demand for incretin-based drugs is anticipated to be influenced by favorable government policies. Governments in many countries are taking steps to subsidize diabetes drugs so that economically weaker sections of the society have access to quality healthcare. Technological innovation in the development of drugs is also expected to provide an impetus to the growth of the market. Availability of rapid acting and long acting insulin analogs is emerging as an effective way of managing both Type 1 and Type 2 diabetes. Demand for incretin-based drugs is increasing in Asia-Pacific, whereas North America and Western Europe are lucrative markets for incretin-based drugs owing to increasing awareness on diabetes diagnosis and management.
Some of the major market players of incretin-based drugs market include AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd and Sanofi S.A. New product launches and approvals are a few strategies adopted by top industry players. In March 2015, Takeda Pharmaceutical got Japanese approval for oral tablet Zarate, a DPP-4 inhibitor. Recently GlaxoSmithKline launched subcutaneous injection of Tanzeum (albiglutide), a GLP-1 agonist for the treatment of type 2 diabetes.
This research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically-supported and industry-validated market data. It also includes projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geography, product type, material type, and end-use.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
By drug type, the incretin-based drugs market can be segmented into,
By formulation, the incretin-based drugs market can be segmented into,
By distribution channel, the incretin-based drugs market can be segmented into,
Our Research Products
The "Full Research Suite" delivers actionable market intel, deep dives on markets or technologies, so clients act faster, cut risk, and unlock growth.
The Leaderboard benchmarks and ranks top vendors, classifying them as Established Leaders, Leading Challengers, or Disruptors & Challengers.
Locates where complements amplify value and substitutes erode it, forecasting net impact by horizon
We deliver granular, decision-grade intel: market sizing, 5-year forecasts, pricing, adoption, usage, revenue, and operational KPIs—plus competitor tracking, regulation, and value chains—across 60 countries broadly.
Spot the shifts before they hit your P&L. We track inflection points, adoption curves, pricing moves, and ecosystem plays to show where demand is heading, why it is changing, and what to do next across high-growth markets and disruptive tech
Real-time reads of user behavior. We track shifting priorities, perceptions of today’s and next-gen services, and provider experience, then pace how fast tech moves from trial to adoption, blending buyer, consumer, and channel inputs with social signals (#WhySwitch, #UX).
Partner with our analyst team to build a custom report designed around your business priorities. From analysing market trends to assessing competitors or crafting bespoke datasets, we tailor insights to your needs.
Supplier Intelligence
Discovery & Profiling
Capacity & Footprint
Performance & Risk
Compliance & Governance
Commercial Readiness
Who Supplies Whom
Scorecards & Shortlists
Playbooks & Docs
Category Intelligence
Definition & Scope
Demand & Use Cases
Cost Drivers
Market Structure
Supply Chain Map
Trade & Policy
Operating Norms
Deliverables
Buyer Intelligence
Account Basics
Spend & Scope
Procurement Model
Vendor Requirements
Terms & Policies
Entry Strategy
Pain Points & Triggers
Outputs
Pricing Analysis
Benchmarks
Trends
Should-Cost
Indexation
Landed Cost
Commercial Terms
Deliverables
Brand Analysis
Positioning & Value Prop
Share & Presence
Customer Evidence
Go-to-Market
Digital & Reputation
Compliance & Trust
KPIs & Gaps
Outputs
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Drugs Glass Packaging Market Analysis - Size, Share, and Forecast Outlook 2025 to 2035
Orphan Drugs Market Size and Share Forecast Outlook 2025 to 2035
Topical Drugs Packaging Market Growth & Forecast 2025 to 2035
Retinal Drugs And Biologics Market
Antiviral Drugs Market Size and Share Forecast Outlook 2025 to 2035
Cytotoxic Drugs Market Analysis – Growth, Trends & Forecast 2025-2035
3D Printed Drugs Market Outlook – Growth, Demand & Forecast 2025-2035
Depression Drugs Market
Parenteral Drugs Packaging Market
Brain Tumor Drugs Market Forecast & Analysis: 2025 to 2035
Infertility Drugs Market Analysis - Size, Share & Forecast 2025 to 2035
Expectorant Drugs Market Trend Analysis Based on Drug, Dosage Form, Product, Distribution Channel, and Region 2025 to 2035
Cannabinoid Drugs Market
Clot Busting Drugs Market Size and Share Forecast Outlook 2025 to 2035
Psychotropic Drugs Market Growth - Industry Trends & Outlook 2025 to 2035
Critical Care Drugs Market Analysis – Trends, Demand & Forecast 2024-2034
Anti-Malarial drugs Market
Antimetabolite Drugs Market Size and Share Forecast Outlook 2025 to 2035
Fish-Oil Based Drugs Market Analysis – Trends, Share & Growth Forecast 2024-2034
Plasma-Derived Drugs Market
Incretin-Based Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
